2022
The importance of an early onset of migraine preventive disease control: A roundtable discussion
Gottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura M, Pavlovic J, Dumas P, Lalvani N, Buse D. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022, 5: 25158163221134593. DOI: 10.1177/25158163221134593.Peer-Reviewed Original ResearchEarly onsetDisease controlPreventive therapyMigraine activityAnti-calcitonin gene-related peptide monoclonal antibodyMigraine preventive therapyBurden of migrainePeptide monoclonal antibodyRoundtable of expertsMigraine preventionTreatment initiationPreventive benefitsClinical studiesTreatment expectationsClinical relevancePatientsDrug AdministrationPatient advocatesTherapy goalsHealthcare professionalsMonoclonal antibodiesRoundtable meetingPreventionGrey literatureProfessionals' perceptions
2020
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results